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CME: Case reports
February’s CME consists of a series of case reports that have been 
received over the past 12 months. Many journals, local and international, 
feature case reports within their pages, and younger doctors in particular 
are encouraged to write up their more interesting cases in this format.
According to Wikipedia, ‘in medicine, a case report is a detailed 
report of the symptoms, signs, diagnosis, treatment and follow-up 
of an individual patient’. Case reports are usually written to provide 
an unusual or novel occurrence of a set of signs and symptoms, or, 
as is the case in some of the reports published this month, unusual 
presentations of a particular disease entity. Case reports often contain 
some kind of literature review of other reported cases, even if only to 
say that the report is of a rare occurrence.
Case reports are, by their very nature, anecdotal and are placed at 
the foot of the hierarchy of clinical evidence, together with case series. 
However, case reports are usually thought to have genuinely useful 
roles in medical research and in evidence-based medicine. 
However, one of the most useful roles of case reports is that of 
medical education, both formally, providing a structure for case-
based learning (which we all did at medical school), and informally, 
for the general reader. In both cases, interesting and unusual 
presentations are helpful to day-to-day practice and will often trigger 
recognition of a diagnosis or pathology in a puzzling clinical case. 
All the case reports presented in this issue of CME are local, 
and selected for their particular usefulness to our younger and less 
experienced colleagues.
Renal disease and haemodialysis in 
HIV­positive patients
An article on morbidity and mortality of black HIV-positive patients 
with end-stage kidney disease receiving chronic haemodialysis in 
South Africa (SA)[1] and an accompanying editorial[2] reveal the extent 
of renal disease in the HIV-positive population. Renal disease affects 
up to 30% of HIV-infected patients. HIV-associated nephropathy 
(HIVAN) is most common and, unless treated with antiretroviral 
therapy (ART), progresses rapidly to end-stage renal disease (ESRD).
ESRD is projected to increase further now that HIV-positive patients 
are living longer on ART and are increasingly manifesting the 
diseases of lifestyle, including hypertension and diabetes.
All HIV-positive patients should be screened for chronic kidney 
disease at first encounter with any health service. This is particularly 
important in view of the fact that HIVAN can occur with high CD4 
counts. Screening should include urinalysis and measurement of kidney 
function. Patients manifesting renal involvement should be fast-tracked 
for ART. Furthermore, being HIV-positive is no longer a contraindication 
to renal transplantation, provided patients are established on ART and 
achieve acceptable CD4 counts and suppressed viral loads.
Linking cervical cancer screening 
to human papillomavirus (HPV) 
vaccination
This issue of SAMJ features the second article on the Vaccine and 
Cervical Cancer Screen (VACCS) project, on linking cervical cancer 
screening to HPV vaccination in the South-West District of Tshwane, 
Gauteng, SA.[3] This study provided the novel opportunity to investigate 
the outcome of cervical cancer screening in mothers and guardians by 
linking this to the vaccination of the grade 4 - 7 girls in their care. New 
molecular screening technology was utilised, permitting self-sampling 
in a home setting with a screen kit offered to female parents and 
guardians (plus an extra one for a friend or family member). The screen 
kit consisted of a tampon with user instructions: women inserted the 
tampon vaginally and removed it after one hour. The used tampon 
was placed in a container with buffer and, together with personal 
information, was returned to the school in a sealed envelope. DNA 
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was extracted from the tampon specimens and tested for any of the 15 
high-risk viral types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 
82), HPV 16 and 18 being the two most oncogenic. Roughly half of the 
women took up the screening opportunity, and molecular screening 
identified cervical cancer risk in 30% and a high risk of future disease 
in 9.1%. Using the school infrastructure as well as mobile phone 
technology, all women received their screen results. 
This is an important development, given the limited success 
registered by the national cervical cancer prevention programme, 
launched in 2000, which offers three Papanicolaou smears per 
lifetime (starting after the age of 30, at 10-year intervals).
Digitalis reappraised
Still here today, but gone tomorrow? Opie[4] suggests that there are 
very few arguments left in favour of the use of digitalis in the control 
of heart rate in atrial fibrillation. Following negative mortality 
data from one large recent study of digitalis in heart failure (HF), 
enthusiasm for further testing for the benefit of digitalis that would 
necessitate a large, multicentre, prospective randomised controlled 
trial is waning. Opie suggests that digoxin, for the indication of HF, 
would not be passed by regulatory agencies on the basis of present 
data. (See also in CME ‘Digoxin therapy in the modern management 
of cardiovascular disease: An unusual but serious complication’[5].)
Why is cancer not a priority in  
South Africa?
An editorial asks the above question.[6] The National Cancer 
Registry (NCR) is an invaluable source of cancer data for the 
country. Established in 1986 as a voluntary, pathology-based 
cancer reporting system, the Registry within the National Health 
Laboratory Service is the principal cancer surveillance system 
in SA. Regulation 380 of the 2011 National Health Act formally 
established the NCR as the main cancer surveillance agency and 
mandated reporting of all confirmed cancers in SA to the NCR. 
The NCR receives over 100 000 cancer reports annually; approxi-
mately 80 000 are new cases, on the basis of which cancer inci dence 
is calculated. Registry data have been used to highlight cancers of 
importance in the SA context. Data from the Johannesburg Cancer 
Case Control Study (JCCCS), conducted by the Cancer Epidemiology 
Research Group, have been used to extensively describe the 
epidemiology of HIV-related cancers and particularly to explore the 
relationship between Kaposi’s sarcoma and HIV. The JCCCS has also 
contributed to risk factor analysis in the International Collabo ration 
of Epidemiological Studies of Cervical Cancer. 
The NCR manages cancer surveillance in the context of SA’s dual 
health system, comprising a large public health infrastructure serving 
approximately 84% of the population and a smaller private health 
system catering to 16%. It is dismaying to learn from Singh et al.[7] 
that private laboratory cancer data reporting, which was consistent 
throughout the early 2000s, was withheld from 2005 to 2007, 
resulting in a 28% under-reporting from private healthcare centres 
(see Fig. 1, reproduced below). Fortunately the impact of withheld 
private data appears to have been minimal in that there was only a 4% 
decrease in overall cancer reporting, reflecting the reality that four 
out of every five SA citizens receive care in public healthcare systems. 
Fortunately, too, relationships with private sector laboratories have 
been renewed and a standard system has been established to receive 
private sector pathology data electronically. 
In an era of growing prioritisation of NCDs and with global 
cancer burdens estimated to increase significantly, the NCR has an 
invaluable role to play in the health and health planning landscape 
of SA. In view of the progressive health developments in the country, 
such as the introduction of National Health Insurance, there is an 
imperative to accurately quantify the cancer burden, and thus the cost 
of cancer services to be provided to the SA population.
Non­communicable diseases (NCDs)
Two articles in this issue address comorbidity and multimorbidity 
in NCDs in the SA setting,[8,9] the former suggesting that future 
clinical guidelines, training of primary care nurses and involvement 
of doctors in the continuum of care should address the complexity 
of patients with NCDs and multimorbidity, and the latter warning 
against mobilisation of scarce resources to implement mass screening 
for diabetes and hypertension in the absence of adequate evidence 
of benefit. 
As is well recognised, the SA healthcare system faces a quadruple 
burden of disease, characterised by HIV/AIDS and tuberculosis, 
injury and violence, maternal and child health issues and NCDs. The 
World Health Organization estimates the burden of NCDs to be two 
to three times higher in SA than in high-income countries. NCDs are 
estimated to contribute 28% to the total burden of disease, and this 
is predicted to increase substantially over the next few decades. In 
the Western Cape, NCDs account for five of the ten leading causes of 
death: ischaemic heart disease, diabetes, cerebrovascular disease, lung 
cancer and chronic obstructive pulmonary disease. NCD distribution 
reflects socioeconomic disparities, with the heaviest burden among 
poor communities in urban areas, posing a developmental challenge 
to the country.[10]
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Fig. 1. Actual and projected case reporting from private laboratories and to 
the NCR, 1995 - 2007.
